{
    "clinical_study": {
        "@rank": "143050", 
        "arm_group": [
            {
                "arm_group_label": "Sequence A", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Sequence B", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Sequence C", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Sequence D", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effects of K-877 on ECG parameters with a\n      focus on cardiac repolarization compared with placebo in healthy adult subjects."
        }, 
        "brief_title": "A Thorough Corrected QT Interval Trial", 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject provides written informed consent before any study specific evaluation is\n             performed.\n\n          -  Subject is a healthy adult male or female volunteer, of any race and ethnicity,\n             between the ages of 18 and 45 years, inclusive.\n\n          -  Subject has a body mass index of 18 to 30 kg/m2, inclusive.\n\n        Exclusion Criteria:\n\n          -  Subject has clinically relevant abnormalities in the screening or check in\n             assessments.\n\n          -  Subject has a supine blood pressure after resting for at least 5 minutes that is\n             higher than 140 mm Hg systolic or 90 mm Hg diastolic, or lower than 90 mm Hg systolic\n             or 60 mm Hg diastolic.\n\n          -  Subject has a supine Heart Rate (HR) (as measured at Screening or Check-in during\n             collection of vital signs) after resting for at least 5 minutes that is outside the\n             range of 40 to 90 beats per minute."
            }, 
            "gender": "Both", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "id_info": {
            "nct_id": "NCT02073084", 
            "org_study_id": "K-877-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D"
                ], 
                "intervention_name": "K-877 Low Dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D"
                ], 
                "intervention_name": "Moxifloxacin 400mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Sequence A", 
                    "Sequence B", 
                    "Sequence C", 
                    "Sequence D"
                ], 
                "intervention_name": "K-877 High Dose", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_contact": {
            "email": "Info@kowaus.com", 
            "last_name": "Roger Morgan, MD, FACS", 
            "phone": "919-433-1600"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "QTcI (QT interval corrected) duration", 
            "time_frame": "24 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073084"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Kowa Research Institute, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kowa Research Institute, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}